Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT04252586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2020
Completion date
June 9, 2021
Enrollment
21 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome, rtt